Hormonal
Caloric restriction interventions restore gut-brain axis communication in obesity by enriching beneficial bacteria (e.g., Akkermansia muciniphila), reducing LPS-mediated endotoxemia, and modulating SCFA production to enhance satiety signaling.
To leverage the gut-brain axis for weight management, reduce your daily caloric intake by 20-40% while ensuring you get adequate nutrients. This specific type of dietary restriction has been shown to improve gut bacteria diversity, reduce inflammation, and boost satiety hormones, making it easier to maintain energy balance.
CR not only affects gut microbiota composition, but also its function... CR promotes functions favouring the production of propionate... CR-mediated SCFA modulation also affects satiety through the production of anorexigenic peptides in the gut (such as PYY and GLP-1)... the abundance of LPS producing bacteria, and thus of LPS, are reduced under CR... this CR-mediated effect may help restore the communication between the gut and the brain
Why this rating
Based on a narrative review citing multiple preclinical and clinical trials, though consensus on specific bacterial shifts is noted as variable.
Source
The Gut–Brain Axis in Obesity: Mechanisms, Development, and Therapeutic Perspectives
Laura Arellano-García et al. · Current Nutrition Reports · 2026
DOI 10.1007/s13668-026-00732-w
More from this paper
- Obesity is associated with gut microbiota dysbiosis characterized by reduced diversity, altered taxonomic abundance, and impaired gut-brain axis communication, leading to dysregulated appetite and energy homeostasis.Good
- GLP-1 receptor agonists (Liraglutide and Semaglutide) promote weight loss and modulate gut microbiota towards a lean-related profile, although clinical data on their specific impact on gut microbiota composition is currently limited.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →